business

Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?

Yahoo Finance · Jun 30, 2026, 1:21 PM · Also reported by 2 other sources

Read full story on Yahoo Finance → More top stories

Also covered by

CNBC French biotech stock soars 31% after new data on experimental medicine MarketWatch Alphabet’s stock slump is a ‘tactical buying opportunity,’ according to one analyst

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?

Also covered by

More in business